INCY•benzinga•
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Summary
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga